We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What Is the Intent Behind AbbVie's Recent Acquisition Spree?
Read MoreHide Full Article
Key Takeaways
AbbVie struck a $1.2B deal to acquire Gilgamesh's mid-stage psychedelic drug for depression.
Since 2024, AbbVie has signed over 30 M&A deals across oncology, neuroscience, and obesity.
Recent buys include Capstan's CAR-T therapy and Gubras amylin analog for obesity treatment.
AbbVie (ABBV - Free Report) has been on an acquisition spree in the past couple of years to bolster the early-stage pipeline, which should drive long-term growth. Though immunology remains its core area, the company is also signing some early-stage deals across various other therapeutic areas, including oncology and neuroscience.
Since the beginning of last year, the company has signed over 30 M&A deals, including promising technologies and innovative mechanisms that can increase the standard of care across various therapeutic areas. A key deal was the April 2025 licensing agreement with Denmark’s Gubra rights to develop a long-acting amylin analog, marking its foray into the obesity space. In August 2025, AbbVie completed the acquisition of Capstan Therapeutics, which added a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy, strengthening its immunology pipeline.
Such transactions have not only broadened AbbVie’s therapeutic footprint but also diversified its pipeline across multiple modalities. The augmented pipeline now includes next-generation immunology candidates, bispecifics, antibody-drug conjugates and innovative therapies for neuropsychiatric and neurodegenerative disorders.
Focus on M&A in 2025
While broader macroeconomic concerns, including Trump-era tariffs and leadership shifts at the FDA, have weighed on deal-making this year, Big Pharma continues to pursue strategic assets in key growth areas.
One of the biggest deals signed this year was by J&J (JNJ - Free Report) , after it completed the $14.6 billion acquisition of Intra-Cellular Therapies to strengthen its neuroscience franchise. After closing the deal in April, J&J added Intra-Cellular’s sole marketed drug Caplyta, which is approved for two indications — schizophrenia and bipolar depression. The deal is a strategic fit for J&J’s existing neuroscience franchise, which includes the antipsychotic drug Invega Sustenna and the depression treatment Spravato.
Shares of AbbVie have outperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a premium to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 15.41 times forward earnings, slightly higher than its industry’s average of 14.79. The stock is also trading above its five-year mean of 12.73.
Image Source: Zacks Investment Research
EPS estimates for 2025 and 2026 have increased in the past 30 days.
Image: Bigstock
What Is the Intent Behind AbbVie's Recent Acquisition Spree?
Key Takeaways
AbbVie (ABBV - Free Report) has been on an acquisition spree in the past couple of years to bolster the early-stage pipeline, which should drive long-term growth. Though immunology remains its core area, the company is also signing some early-stage deals across various other therapeutic areas, including oncology and neuroscience.
Earlier this week, AbbVie entered into a definitive agreement to acquire private neuroscience biotech Gilgamesh Pharmaceuticals’ lead pipeline drug for a total deal value of nearly $1.2 billion. Once closed, the company will add bretisilocin — a novel, psychedelic compound being developed in a mid-stage study for major depressive disorder (MDD) — to its neuroscience pipeline.
Since the beginning of last year, the company has signed over 30 M&A deals, including promising technologies and innovative mechanisms that can increase the standard of care across various therapeutic areas. A key deal was the April 2025 licensing agreement with Denmark’s Gubra rights to develop a long-acting amylin analog, marking its foray into the obesity space. In August 2025, AbbVie completed the acquisition of Capstan Therapeutics, which added a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy, strengthening its immunology pipeline.
Such transactions have not only broadened AbbVie’s therapeutic footprint but also diversified its pipeline across multiple modalities. The augmented pipeline now includes next-generation immunology candidates, bispecifics, antibody-drug conjugates and innovative therapies for neuropsychiatric and neurodegenerative disorders.
Focus on M&A in 2025
While broader macroeconomic concerns, including Trump-era tariffs and leadership shifts at the FDA, have weighed on deal-making this year, Big Pharma continues to pursue strategic assets in key growth areas.
One of the biggest deals signed this year was by J&J (JNJ - Free Report) , after it completed the $14.6 billion acquisition of Intra-Cellular Therapies to strengthen its neuroscience franchise. After closing the deal in April, J&J added Intra-Cellular’s sole marketed drug Caplyta, which is approved for two indications — schizophrenia and bipolar depression. The deal is a strategic fit for J&J’s existing neuroscience franchise, which includes the antipsychotic drug Invega Sustenna and the depression treatment Spravato.
Last month, Eli Lilly (LLY - Free Report) completed the acquisition of cardiology-focused Verve Therapeutics in a deal valued at up to $1.3 billion. This transaction marked LLY’s third targeted M&A deal this year. Earlier in January, it signed a $2.5 billion deal for Scorpion Therapeutics’ experimental oncology drug. In May, Lilly agreed to acquire SiteOne Therapeutics for $1 billion to strengthen its neuroscience pipeline. Such deals suggest that LLY’s M&A strategy is selective, focusing on long-term strength across therapeutic areas beyond its dominant presence in obesity.
ABBV’s Price Performance, Valuation and Estimates
Shares of AbbVie have outperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a premium to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 15.41 times forward earnings, slightly higher than its industry’s average of 14.79. The stock is also trading above its five-year mean of 12.73.
Image Source: Zacks Investment Research
EPS estimates for 2025 and 2026 have increased in the past 30 days.
Image Source: Zacks Investment Research
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.